Lexaria Bioscience (LEXX.US): The 2024 Q2 financial report achieved revenue of US$145,000, with a previous value of US$350.2 million; earnings per share of -0.06 dollars, previous value of -0.22 dollars, and expected value of -0.10 dollars.
Lexaria Bioscience(LEXX.US)：2024年Q2财报实现营收14.5万美元，前值为3.502万美元；每股收益为-0.06美元，前值为-0.22美元，预期值为-0.10美元。
Lexaria Bioscience (LEXX.US): The 2024 Q2 financial report achieved revenue of US$145,000, with a previous value of US$350.2 million; earnings per share of -0.06 dollars, previous value of -0.22 dollars, and expected value of -0.10 dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.